GlobeNewswire Inc | Nov 10, 2021 07:00AM EST

November 10, 2021

UPPSALA, Sweden, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Olink) (Nasdaq: OLK) today announced its financial results for the third quarter of 2021.

Highlights:

-- Revenue was $20.0 million in the third quarter of 2021, representing year over year growth of 82% on a reported basis and 79% on a constant currency adjusted like-for-like basis. Revenues for the nine months ending 30 September 2021 were $51.3 million, representing year over year growth of 91%. -- Adjusted EBITDA was ($7.9) million in the third quarter of 2021, as compared to $2.9 million in the third quarter of 2020 -- Net loss was ($5.5) million in the third quarter of 2021, as compared to ($0.1) million in the third quarter of 2020 -- Olink reiterates its expectations for full year 2021 revenue to be in the range of $90 million to $92 million, and its plans to continue to accelerate investments into its platform to further accelerate growth -- First major data delivery and revenue recognition on the UK Biobank Pharma Proteomics Project (UKBB), one of the worlds largest studies of blood protein biomarkers conducted to date -- Second full quarter with the Explore Kit offering in the market; cumulative number of external kit customers was 21 at the end of the third quarter of 2021 -- Explore accounted for 63% of total revenues in Q3. Explore Kit revenue accounted for 15% of Explore revenues in Q3.

Our dedicated team delivered very strong yearly growth of 82%, and $20.0 million in third quarter revenue, despite headwinds from the COVID resurgence and the timing of some customer activity. We are enthusiastic about the customer feedback and acceptance of the Explore service and kit offerings, as well as the funnel of opportunity for Explore as we head into year end, said Jon Heimer, CEO of Olink Proteomics. During the quarter, the first major data delivery on the UK Biobank Pharma Proteomics Project marked an important milestone for the field of proteomics.

Third quarter financial results:Our strong growth as a commercial organization was driven by continued robust execution, as well as our newest product offering, Explore, which accounted for 63% of total revenues in Q3. We remain on track with our investments into the business, the buildup of our Explore externalization pipeline, and our financial guidance of $90 to $92 million for the full year, said Oskar Hjelm, CFO of Olink Proteomics.

Total revenue for the third quarter of 2021 was $20.0 million, as compared to $11.0 million for the third quarter of 2020. Revenue growth was driven primarily by the Explore platform.

Analysis services revenue for the third quarter of 2021 was $15.1 million, as compared to $6.0 million for the third quarter of 2020.

Kits revenue for the third quarter of 2021 was $3.7 million, as compared to $3.2 million for the third quarter of 2020. Kits revenue was impacted by the timing of installations and shipments, in part due to COVID-19 related supply chain friction, which delayed work on certain projects.

Other revenue was $1.2 million for the third quarter of 2021, as compared to $1.8 million for the third quarter of 2020.

By geography, revenue during the third quarter of 2021 was $6.9 million in North America, $11.8 million in EMEA (including Sweden), and $1.3 million in China and RoW (including Japan).

Adjusted gross profit was $13.1 million in the third quarter of 2021, as compared to $8.1 million in the third quarter of 2020.

By segment, adjusted gross profit margin for analysis services for the third quarter of 2021 was 59% as compared to 75% in the third quarter of 2020. The decrease in adjusted gross profit percentage is primarily related to reduced operational efficiency associated with the new product offerings and an increase in personnel costs as we have increased our lab capacity. In addition, as we anticipated the UKBB service delivery further reduced our service gross margin.

Adjusted gross profit margin for kits was 91% for the third quarter of 2021, as compared to 83% for the third quarter of 2020.

Adjusted gross profit margin for other was 74% for the third quarter 2021, as compared to 54% for the third quarter of 2020.

Total operating expenses for the third quarter of 2021 were $24.1 million, as compared to $8.6 million for the third quarter of 2020. The increase was largely due to continued investment in commercial organization, research and development and additional cost as a public company.

Net loss for the third quarter of 2021 was ($5.5) million, as compared to ($0.1) million for the third quarter of 2020.

Net loss per share for the third quarter of 2021 was ($0.05) based on a weighted average number of outstanding shares of 119,007,062, as compared to ($0.20) in the third quarter of 2020 based on a weighted average number of outstanding shares of 22,900,000.

Adjusted EBITDA was ($7.9) million for the third quarter of 2021, as compared to $2.9 million for the third quarter of 2020.

2021 guidance:The company expects full year 2021 revenue to be in the range of $90 million to $92 million. We plan to continue to accelerate investments to further accelerate growth of the company.

Webcast and conference call detailsOlink will host a conference call to discuss the third quarter financial results before the market opens on November 10, 2021 at 8:00 a.m. Eastern Time U.S. The dial-in numbers are (833) 562-0120 for domestic callers or (661) 567-1096 for international callers, followed by Conference ID: 3089822. A live webcast of the conference call will be available on the Investors section of the Company's website at https://investors.olink.com/investor-relations. The webcast will be archived and available for replay for at least 90 days after the event.

Olink virtual investor day with proteomics KOLsOn November 15th, 2021, from 12:30pm to 3:30pm ET, Olink will host a virtual investor day, providing direct access to key opinion leaders from leading universities and BioPharma companies, discussing exciting research projects where Olink is a proud contributor, while also providing an overview of Olinks commercial plans.

2022 annual general meeting of shareholdersOlink will hold its 2022 annual general meeting of shareholders in Uppsala, Sweden, on April 7, 2022. Shareholders are entitled to have items addressed at the annual general meeting if the request has been submitted to the Board of Directors not later than seven weeks prior to the annual general meeting.

Statement regarding use of non IFRS financial measuresWe present certain non-IFRS financial measures because they are used by our management to evaluate our operating performance and formulate business plans. We believe that the use of these non-IFRS measures facilitates investors assessment of our operating performance. We caution readers that amounts presented in accordance with our definitions of Adjusted EBITDA, Adjusted Gross Profit and Adjusted Gross Profit Percentage may not be the same as similar measures used by other companies. Not all companies and Wall Street analysts calculate the non-IFRS measures we use in the same manner. We compensate for these limitations by reconciling each of these non-IFRS measures to the nearest IFRS performance measure, which should be considered when evaluating our performance. We encourage you to review our financial information in its entirety and not rely on a single financial measure.

Use of forward-looking statementsThis press release contains forward-looking statements that are based on managements beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our 2021 revenue outlook, our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words may, will, could, would, should, expect, intend, plan, anticipate, believe, estimate, predict, project, potential, continue, ongoing or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Registration Statement on Form F-1, as amended (File No. 333-257842) and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

About OlinkOlink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.

IR Contact Media ContactJan Medina, CFA, VP Investor Relations & Andrea Prander, CorporateCapital Markets Communications ManagerMobile: +1617802 4157 Mobile: + 46768775 275jan.medina@olink.com andrea.prander@olink.com

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND OTHER COMPREHENSIVE INCOME (UNAUDITED)

Three months ended Nine months ended September 30, September 30,Amounts inthousands of Note 2021 2020 2021 2020 US DollarsRevenue 4 $ 19,974 $ 10,997 $ 51,290 $ 26,879 Cost of goods (7,565 ) (3,179 ) (18,384 ) (9,019 )sold Gross profit 12,409 7,818 32,906 17,860 Selling (9,035 ) (2,777 ) (21,718 ) (8,446 )expensesAdministrative (11,086 ) (4,374 ) (35,669 ) (12,209 )expensesResearch anddevelopment (4,210 ) (1,330 ) (13,419 ) (7,423 )expensesOtheroperating 276 (94 ) 1,039 (109 )income/(loss)Operating loss (11,646 ) (757 ) (36,861 ) (10,327 )Interest (57 ) (1,186 ) (2,010 ) (5,444 )expenseForeignexchange gain/ 4,853 2,042 (648 ) 868 (loss)Otherfinancial 18 (147 ) (1,738 ) (578 )income/(expense) Loss before (6,832 ) (48 ) (41,257 ) (15,481 )taxIncome taxbenefit/ 5 1,361 (57 ) 10,890 2,211 (expense)Net loss forthe period(Attributable $ (5,471 ) $ (105 ) $ (30,367 ) $ (13,270 )toshareholdersof the Parent)Basic anddiluted loss 10 $ (0.05 ) $ (0.20 ) $ (0.37 ) $ (1.28 )per share Othercomprehensive (loss)/income:Items that maybereclassified to profit orloss:Exchangedifferencesfrom (16,703 ) 10,326 (24,089 ) 10,226 translation offoreignoperationsOthercomprehensive(loss)/ income (16,703 ) 10,326 (24,089 ) 10,226 for theperiod, net oftaxTotalcomprehensive(loss)/ income $ (22,174 ) $ 10,221 $ (54,456 ) $ (3,044 )for theperiod, net oftaxTotalcomprehensive(loss)/ incomefor the period $ (22,174 ) $ 10,221 $ (54,456 ) $ (3,044 )(Attributableto shareholderof the Parent)

INTERIM CONDENSED CONSOLIDATED BALANCE SHEET

As of As ofAmounts in thousands of US Dollars Note September 30, December 31, 2021 2020 (Unaudited)ASSETS Non-current assets Intangible assets $ 319,948 $ 347,387 Property, plant and equipment 8,564 5,774 Right-of-use asset 8,692 4,684 Deferred tax assets 5 11,730 37 Other long-term receivables 429 133 Total non-current assets 349,363 358,015 Current assets Inventories 25,976 20,826 Trade receivables 22,394 33,482 Other receivables 4,280 2,856 Prepaid expenses and accrued income 10,420 1,491 Cash at bank and in hand 140,156 8,655 Total current assets 203,226 67,310 TOTAL ASSETS $ 552,589 $ 425,325 EQUITY Share capital 6 30,964 27,224 Other contributed capital 6 503,953 257,774 Reserves 15,271 39,360 Accumulated losses (55,025 ) (24,658 )Total equity attributable to $ 495,163 $ 299,700 shareholders of the ParentLIABILITIES Non-current liabilities Interest-bearing loans and borrowings 6, 7 5,144 63,965 Deferred tax liabilities 5 28,060 33,193 Total non-current liabilities 33,204 97,158 Current liabilities Interest-bearing loans and borrowings 6, 7 3,010 2,146 Accounts payable 5,216 6,658 Current tax liabilities 198 506 Other current liabilities 15,798 19,157 Total current liabilities 24,222 28,467 Total liabilities $ 57,426 $ 125,625 TOTAL EQUITY AND LIABILITIES $ 552,589 $ 425,325

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)

Nine months ended September 30,Amounts in thousands of US Dollars Note 2021 2020 Operating activities Loss before tax $ (41,257 ) $ (15,481 )Adjustments reconciling loss before tax to operating cash flows:Depreciation and amortization 11,176 9,056 Net finance expense 4,396 5,154 Loss on sale of assets 36 - Share based payment expense 6 636 - Changes in working capital: (Increase) in inventories (6,723 ) (3,375 )Decrease in accounts receivable 9,194 7,579 (Increase) in other current (8,804 ) (19 )receivablesIncrease in trade payables (1,041 ) 1,010 (Decrease)/Increase in other current (1,821 ) 7,692 liabilitiesInterest paid (2,192 ) (3,777 )Tax paid (2,618 ) (4,577 )Cash flow used in operating (39,018 ) $ 3,262 activitiesInvesting activities Purchase of intangible assets (4,338 ) (6,234 )Purchase of property, plant and (4,784 ) (2,771 )equipmentProceeds from sale of property, plant 145 - and equipmentAcquisition of subsidiaries, net of - (4,593 )cash acquiredDecrease/(Increase) in other (301 ) 23 non-current financial assetsCash flow used in investing $ (9,278 ) $ (13,575 )activitiesFinancing activities Proceeds from issue of share capital 6 264,706 13,631 Share issue costs 6 (19,484 ) - Proceeds from interest-bearing loans 2,311 8,000 and borrowingsRepayment of interest-bearing loans 7 (65,627 ) - and borrowingsPayment of principal portion of lease (1,952 ) (1,006 )liabilityCash flow from financing activities $ 179,954 $ 20,625 Net cash flow during the period 131,658 10,312 Cash at bank and in hand at the 8,655 6,162 beginning of the periodNet foreign exchange difference (157 ) 211 Cash at bank and in hand at the end $ 140,156 $ 16,685 of the period

A reconciliation of Adjusted EBITDA to operating loss, the most directly comparable IFRS measure, is set forth below:

Three months ended Nine months ended September 30, September 30,Amounts in thousands of 2021 2020 2021 2020U.S. DollarsOperating loss (11,646 ) (757 ) (36,861 ) (10,327 )Add: Amortization 2,650 2,570 8,098 7,230 Depreciation 1,106 732 3,078 1,826 EBITDA (7,890 ) 2,545 (25,685 ) (1,271 )Management Adjustments 39 399 7,861 1,482 Adjusted EBITDA (7,851 ) 2,944 (17,824 ) 211

Reconciliations of Adjusted Gross Profit to gross profit, the most directly comparable IFRS measure, are set forth below:

Three months ended Nine months ended September 30, September 30,Amounts in thousands ofU.S. Dollars, unless 2021 2020 2021 2020otherwise statedRevenue 19,974 10,997 51,290 26,879 Cost of goods sold (7,565 ) (3,179 ) (18,384 ) (9,019 )Gross Profit 12,409 7,818 32,906 17,860 Gross Profit % 62.1 % 71.1 % 64.2 % 66.4 %Less: Inventory fair value step - 7 - 260 upDepreciation charges 691 324 1,892 715 Adjusted Gross Profit 13,100 8,149 34,798 18,835 Adjusted Gross Profit % 65.6 % 74.1 % 67.8 % 70.1 %